Cytokines and Parkinson's Disease

* 100050 doi 10. 11669 /cpj. 2014. 20. 001 R965 A 1001-2494 2014 20-1773 - 05 Cytokines and Parkinson's Disease XIE Tao DU Guan-hua * Beijing Key Laboratory of Drug Targets Identification and Drug Screening Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 China ABSTRACT OBJECTIVE To review the role of cytokines played in Parkinson to direct the treatment of the disease from the prospective of cytokines. METHODS This paper had consulted analysed concluded and summarized research progress of the functions of cytokines in Parkinson's disease. RESULTS AND CONCLUSION Cytokines as inflammatory mediators is involved in Parkinson. Some cytokines can contribute to the progress and development by playing the role of proinflammatory. Others however may play the role of anti-inflammatory to slow down the progress of or as a protective agent to against the disease. KEY WORDS Parkinson's disease dopamine cytokines inflammatory Parkinson's disease 1 2 interleukin IL colony stimulating factor 3 CSF interferon IFN tumor necrosis factor TNF growth factor Lewy 4 T 5 1 IL IL 6 7 - T 8 IL 37 IL IL-1 ~ IL-37 1. 1 IL-1 IL-1 IL-1α IL- 2013ZX09102106 * Tel /Fax 010 63165184 E-mail dugh@ imm. ac. cn 1773

IL-1-23 12 IL-1 IL-10 IL-10-819 T /C 1 IL- 24 1 2IL-1 1. 4 IL-12 3IL-1 T 13 4IL-1β IL-12 IL- α-synuclein 10 Lewy 5 IL-15 IL-1β T IL-15 1β 2 IL-1 IL-10 IL- 9 6-6-OHDA 10 6-OHDA IL-1β 20 1- -4- -1 2 3 6- CD4 + T IL- MPTP 10 21 - IL-1 ROS NO 22 inos NO MPTP 10 IL-10 IL-1 MPTP IL-10 11 MPTP -1 inos IL-10 1. 2 IL-6 25 IL-18 IL-6 T IL-18 607C / A 14 IL-6 Hirsch 2 CSF IL-6 Blum CSF Stypula IL-6 IL-6 α- G-CSF tau 15 M-CSF - α- GM-CSF multi-csf IL-3 IL-6 16 LPS 2. 1 G-CSF IL-6 G-CSF 19. 6 10 3 17 G-CSF IL-6-174 18 IL-6 1. 3 IL-10 G-CSF IL-10 MPTP 13 d 40 μg kg - 1 G-CSF MPTP IL-10 26 G-CSF 6-OHDA IL-10 27 G-CSF LPS MPTP IL-10 28 G-CSF IL-10 19 6-OHDA G-CSF Bcl-2 1774 Chin Pharm J 2014 October Vol. 49 No. 20 2014 10 49 20

36 3 TNF TNF T 43 BDNF BDNF mrna TNF-α TNF-β Bax PC12 29 G- CSF neurotrophic factors NTF G-CSF PI3K /Akt 30 2. 2 GM-CSF MPTP 6-OHDA GM-CSF GM-CSF GM-CSF GM- CSF 31-32 GM-CSF PC12 GM-CSF MPTP 33 GM-CSF brain-derived neurotrophic factor BD- 34 35 GM-CSF NF glial-derived neurotrophic 2 factor GDNF neurturin 42 Bcl-2 Bax 4. 1 BDNF GM-CSF BDNF TNF MPTP 6-OHDA 37 6-OHDA BDNF TNF BDNF trkb NT-3 trkc lenti-dn-tnf 38 lenti- α- DN-TNF Bialecka TNF-308 BDNF 44 TNF-308AA 39 BDNF TNF-α MPTP BDNF TNF-α 4. 2 GDNF IL-1β TNF-α NO GDNF 40 LPS EGCG EGCG TNF-α GDNF BDNF GDNF TNF-α 41 TNF-α GDNF A GDNF GDNF 1 Ras /MAPK PI3K /Akt Ca 2 + 4 growth factor BDNF BDNF 2 NTFs /Src SFKs 3GDNF MEK1 /2 ERK1 /2 1775

4. 3 Neurturin astrocytes J. Molecular Neurobiol 2013 17 3 1-11. 8 DELEIDI M GASSER T. The role of inflammation in sporadic Neurturin GDNF and familial Parkinson's disease J. Cell Mol Life Sci 2013 70 22 4259-4273. GDNF 2 9 POTT GODOY M C TARELLI R FERRARI C C et al. Central GFRαs RET GFRαs 4 GFRα1 ~ GFRα4 Neurturin GFRα2 and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson' s disease J. Brain 2008 131 7 1880-1894. Neurturin GFRα2 Ret Ret 10 KIM H S SUH Y H. Minocycline and neurodegenerative diseases J. Behav Brain Res 2009 196 2 168-179. Ret-Shc-Grb2 11 CORBETT G T ROY A PAHAN K. Gemfibrozil a lipid-lowering drug upregulates IL-1 receptor antagonist in mouse cortical Ras Raf MAPK neurons Implications for neuronal self-defense J. J Immunol 2012 189 2 1002-1013. 12 LOFRUMENTO D D NICOLARDI G CIANCIULLI A et al. 5 Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease Possible role of SOCS-1 in reducing proinflammatory responses J. Innate Immun 2014 20 3 249-260. 13 WANG X CHEN S MA G et al. Involvement of proinflammatory factors apoptosis caspase-3 activation and Ca disturbance in microglia activation-mediated dopaminergic cell degeneration - J. Mech Ageing Dev 2005 126 12 1241-1254. 14 HOFMANN K W SCHUH A F S SAUTE J et al. Interleukin- 6 serum levels in patients with Parkinson' s disease J. Neurochem Res 2009 34 8 1401-1404. 15 BICK R J POINDEXTER B J KOTT M M et al. Cytokines disrupt intracellular patterns of Parkinson' s disease-associated pro- IL-1 teins alpha-synuclein tau and ubiquitin in cultured glial cells IL-10 - J. Brain Res 2008 121 7 203-212. IL-12 IL-15 IL-15 16 KLEGERIS A GIASSON B I ZHANG H et al. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in hu- man astrocytes and astrocytoma cells J. FASEB J 2006 20 TNF-α 12 2000-2008. 17 BEYNON A L BROWN M R WRIGHT R et al. Ghrelin inhibits LPS-induced release of IL-6 from mouse dopaminergic neurones J. J Neuroinflam 2013 10 1 40. 18 CHU K ZHOU X LUO B Y. Cytokine gene polymorphisms and Parkinson's disease A meta-analysis J. Can J Neurol Sci 2012 39 1 58-64. 19 RENTZOS M NIKOLAOU C ANDREADOU E et al. Circulating interleukin-10 and interleukin-12 in Parkinson's disease J. Acta Neurol Scand 2009 119 5 332-337. 20 JOHNSTON L C SU X MAGUIRE-ZEISS K et al. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's REFERENCES 1 SCHAPIRA A H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease J. Lancet Neurol 2008 7 1 97-109. 2 COOKSON M R VAN DER BRUG M. Cell systems and the toxic mechanism s of α-synuclein J. Exp Neurol 2008 209 1 5-11. 3 YACOUBIAN T A STANDAERT D G. Targets for neuroprotection in Parkinson' s disease J. Biochim Biophys Acta 2009 1792 7 676-687. 4 FRITSCH T SMYTH K A WALLENDAL M S et al. Parkinson disease Research update and clinical management J. South Med J 2012 105 12 650-656. disease J. Mol Ther 2008 16 8 1392-1399. 21 XIN J WAINWRIGHT D A MESNARD N A et al. IL-10 within the CNS is necessary for CD4 + T cells to mediate neuroprotection J. Brain Behav Immun 2011 25 5 820-829. 22 KUTER K KOLASIEWICZ W GOLEMBIOWSKA K et al. Partial lesion of the dopaminergic innervation of the ventral striatum induces "depressive-like" behavior of rats J. Pharmacol Rep 2011 63 6 1383-1392. 23 SCHWENKGRUB J JONIEC-MACIEJAK I SZNEJDER-PACHO LEK A et al. Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease J. Pharmacol Rep 2013 65 1 44-49. 5 PHANI S LOIKE J D PRZEDBORSKI S. Neurodegeneration 24 LI D HE Q LI R et al. Interleukin-10 promoter polymorphisms and inflammation in Parkinson's disease J. Parkinson Relat Disord 2012 18 1 207-209. 6 KHANDELWAL P J HERMAN A M MOUSSA C E. Inflammation in the early stages of neurodegenerative pathology J. J Neuroimmunol 2011 238 1-2 1-11. in Chinese patients with Parkinson's disease J. Neurosci Lett 2012 513 2 183-186. 25 RENTZOS M ROMBOS A. The role of IL-15 in central nervous system disorders J. Acta Neurol Scand 2012 125 2 77-82. 26 MEUER K PITZER C TEISMANN P et al. Granulocyte-colony 7 NIRANJAN R. The Role of inflammatory and oxidative stress stimulating factor is neuroprotective in a model of Parkinson' s mechanisms in the pathogenesis of Parkinson's disease Focus on disease J. J Neurochem 2006 97 3 675-686. 1776 Chin Pharm J 2014 October Vol. 49 No. 20 2014 10 49 20

27 LIAO C H CHEN S Y KUO J S et al. Reduction of motor disorder in 6-OHDA-induced severe parkinsonism rats by post treatment with granulocyte-colony stimulating factor J. Chin J Physiol 2013 56 3 147-154. 28 SONG S SAVA V ROWE A et al. Granulocyte-colony stimulating factor G-CSF enhances recovery in mouse model of Parkinson's disease J. Neurosci Lett 2011 487 2 153-157. 29 MEUER K PITZER C TEISMANN P et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson' s disease J. J Neurochem 2006 97 3 675-686. 30 SCHNEIDER A KRUGER C STEIGLEDER T et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis J. J Clin Invest 2005 115 8 2083-2098. 31 HENZE C HARTMANN A LESCOT T et al. Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism Role of granulocyte macrophage colony-stimulating factor J. J Neurochem 2005 95 4 1069-1077. 32 SCHABITZ W R KRUGER C PITZER C et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor GM-CSF J. J Cereb Blood Flow Metab 2008 28 1 29-43. 33 KIM N K CHOI B H HUANG X et al. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1 2 3 6-tetrahydropyridine-induced murine Parkinson' s disease model J. Eur J Neurosci 2009 29 5 891-900. 34 MANGANO E N PETERS S LITTELJOHN D et al. Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease J. Neurobiol Dis 2011 43 1 99-112. 35 CHOUDHURY M E SUGIMOTO K KUBO M et al. A cytokine mixture of GM-CSF and IL-3 that induces a neuroprotective phenotype of microglia leading to amelioration of 6-OHDA -induced Parkinsonism of rats J. Brain Behav 2011 1 1 26-43. 36 KOSLOSKI L M KOSMACEK E A OLSON K E et al. GM- CSF induces neuroprotective and anti-inflammatory responses in 1- methyl-4-phenyl-1 2 3 6-tetrahydropyridine intoxicated mice J. J Neuroimmunol 2013 265 1-2 1-10. 37 WHITTON P S. Inflammation as a causative factor in the aetiology of Parkinson's disease J. Br J Pharmacol 2007 150 8 963-976. 38 HARMS A S BARNUM C J RUHN K A et al. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease J. Mol Ther 2011 19 1 46-52. 39 BIALECKA M KLODOWSKA-DUDA G KURZAWSKI M et al. Interleukin-10 IL-10 and tumor necrosis factor alpha TNF gene polymorphisms in Parkinson's disease patients J. Parkinson Relat Disord 2008 14 8 636-640. 40 HIRSCH E C HUNOT S. Neuroinflammation in Parkinson's disease A target for neuroprotection J. Lancet Neurol 2009 8 4 382-397. 41 AL-AMRI J S HAGRAS M M MOHAMED I M. Effect of epigallocatechin-3-gallate on inflammatory mediators release in LPS-induced Parkinson's disease in rats J. Indian J Exp Biol 2013 51 5 357-362. 42 PETERSON A L NUTT J G. Treatment of Parkinson' s disease with trophic factors J. Neurotherapeutics 2008 5 2 270-280. 43 BAQUET Z C BICKFORD P C JONES K R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta J. J Neurosci 2005 25 26 6251-6259. 44 VON BOHLEN UND HALBACH O MINICHIELLO L UNSICK- ER K. Haploinsufficiency for trkb and trkc receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra J. FASEB J 2005 19 12 1740-1742. 45 KORDOWER J H HERZOG C D DASS B et al. Delivery of neurturin by AAV2 CERE-120 -mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys J. Ann Neurol 2006 60 6 706-715. 46 HERZOG C D DASS B HOLDEN J E et al. Striatal delivery of CERE-120 an AAV2 vector encoding human neurturin enhances activity of the dopaminergic nigrostriatal system in aged monkeys J. Mov Disord 2007 22 8 1124-1132. 2014-01-10 1777